Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I Study of Cellular Immunotherapy Using T Cells Lentivirally Transduced to Express a Cd33-Specific Chimeric Antigen Receptor for Patients With Cd33+ Relapsed/Refractory Acute Myeloid Leukemia

NCT05672147 is registered in ClinicalTrials.gov with City of Hope Medical Center as lead sponsor.

NCT NCT05672147
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05672147 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I Study of Cellular Immunotherapy Using T Cells Lentivirally Transduced to Express a Cd33-Specific Chimeric Antigen Receptor for Patients With Cd33+ Relapsed/Refractory Acute Myeloid Leukemia
Lead sponsor
City of Hope Medical Center
Phase
Phase 1
Overall status
Recruiting
Start date
December 7, 2023
Completion date
September 3, 2028
Enrollment
27 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

acute myeloid leukemia, recurrent adult acute myeloid leukemia, refractory acute myeloid leukemia, secondary acute myeloid leukemia